Language in the federal appropriations bill would allow Medicare coverage of FDA‑approved multi‑cancer early detection (MCED) tests without waiting for U.S. Preventive Services Task Force endorsement, setting reimbursement equal to that for a multi‑target stool DNA colorectal test ($509) and phasing eligibility from ages 50–65 in 2029 upward. The provision reflects sustained pressure from diagnostics companies and lawmakers to fast‑track reimbursement for MCEDs and could reshape commercial dynamics for firms selling blood‑based cancer screening assays.